Kevin M. Sullivan, MD, assistant professor of Medicine at Hofstra/Northwell Health School of Medicine, discusses the current treatment options for patients with lung cancer harboring an ALK mutation.

The current frontline standard of care for ALK-mutated lung cancer are ALK-directed therapies. Most physicians are using alectinib (Alecensa) now for the treatment of these patients, Sullivan says. Upon progression, there are a number of new agents available, such as tyrosine kinase inhibitors (TKIs) lorlatinib (Lorbrena) and brigatinib (Alunbrig), for these patients.

Upon progression following initial frontline therapy, many physicians also send out samples for further testing. Blood circulating tumor DNA (ctDNA) testing is used to discover any evidence of genomic alterations that might guide systemic therapy choices. Other ALK-directed compounds are in development, including other TKIs. These agents are still early in development at this point, Sullivan says.

See more information on the ALK inhibitors coming down the pipeline here: [ Ссылка ]-

свернуть